← All organizations
Highest phase reached
Phase 3
First clinical trial
Sep 1, 2011Last known activity
Mar 27, 2025
Timeline
2000s
- Jun 1, 2001
Biocad— Founded
Drugs by trial phase (52 distinct, 90 trials)
Phase 3 (38 own, 0 via acquisition)
Phase 2 (5 own, 0 via acquisition)
Indications
Studied for
- Acquired Immunodeficiency Syndrome
- Anemia
- Arthritis
- Arthritis, Psoriatic
- Arthritis, Rheumatoid
- Breast Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Renal Cell
- Cholangitis
- Coinfection
- Hemoglobinuria
- Hemoglobinuria, Paroxysmal
- Hepatitis
- Hepatitis A
- Hepatitis C
- Hepatitis C, Chronic
- HIV Infections
- Immunologic Deficiency Syndromes
- Kidney Diseases
- Kidney Failure, Chronic
- Leukocytosis
- Liver Cirrhosis
- Liver Cirrhosis, Biliary
- Lung Neoplasms
- Lymphoma
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Macular Degeneration
- Melanoma
- Multiple Sclerosis
- Multiple Sclerosis, Relapsing-Remitting
- Neutropenia
- Psoriasis
- Renal Insufficiency, Chronic
- Sclerosis
- Spondylitis
- Spondylitis, Ankylosing
- Thrombosis
- Uterine Cervical Neoplasms
- Venous Thrombosis
- Wet Macular Degeneration
Recent trials (50)
- NCT07136389OfficialPhase 1Mar 27, 2025
- NCT07136389Lead sponsorPhase 1Mar 27, 2025
- NCT07181694OfficialPhase 1Mar 12, 2025
- NCT07181694Lead sponsorPhase 1Mar 12, 2025
- NCT07119372Lead sponsorPhase 3Mar 1, 2025
- NCT06700096Lead sponsorPhase 3Dec 31, 2024
- NCT06700096OfficialPhase 3Dec 31, 2024
- NCT06668792Lead sponsorPhase 2Nov 30, 2024
- NCT06640517Lead sponsorPhase 3Aug 8, 2024
- NCT07008547Lead sponsorPhase 3Jul 30, 2024
- NCT07108309OfficialPhase 2Jul 15, 2024
- NCT07108309Lead sponsorPhase 2Jul 15, 2024
- NCT06715540Lead sponsorPhase 1Mar 29, 2024
- NCT06715540OfficialPhase 1Mar 29, 2024
- NCT06640530Lead sponsorPhase 3Mar 21, 2024
Details
- Founded
- St Petersburg, RU Jun 1, 2001
- Last known activity
- Mar 27, 2025
Notes
CRO